Form 4: Galectin Therapeutics CMO Sells 60,000 Shares

Galectin Therapeutics' Chief Medical Officer, Khurram Jamil, sold 60,000 shares of common stock in early January 2026, following the vesting of Restricted Stock Units, as part of a pre-arranged 10b5-1 plan.

Summary

• Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc. (GALT), reported transactions involving the company's common stock.
• On January 2, 2026, 60,000 Restricted Stock Units (RSUs) vested and converted into 60,000 shares of common stock for no additional consideration.
• Following the vesting, Mr. Jamil sold 13,055 shares of common stock on January 2, 2026, at a weighted average price of $4.1968 per share.
• An additional 25,499 shares were sold on January 5, 2026, at a weighted average price of $3.8985 per share.
• The remaining 21,446 shares were sold on January 6, 2026, at a weighted average price of $3.6466 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 plan adopted by Mr. Jamil on April 17, 2025.
• After these transactions, Mr. Jamil beneficially owns 0 shares of Galectin Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these transactions were pre-planned under a Rule 10b5-1 plan mitigates concerns about opportunistic selling based on non-public information. The vesting of RSUs is a standard compensation event.

Positives

• The vesting of 60,000 Restricted Stock Units for no additional consideration represents a positive compensation event for the Chief Medical Officer.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating that the sales were scheduled in advance and not based on immediate, non-public information.

Negatives

• The sale of all 60,000 shares of common stock by the Chief Medical Officer, even if pre-planned, could be perceived by some investors as a reduction in direct equity alignment with the company's future performance.

Risks

• Investor perception of insider selling, even under a 10b5-1 plan, could potentially lead to negative sentiment or increased scrutiny of the company's stock performance.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are a routine part of executive compensation and personal financial planning, often managed through 10b5-1 plans in the biotechnology sector.

Corporate Governance

Stakeholder Impact

• Shareholders may observe the reduction in the Chief Medical Officer's direct equity stake, which could influence their perception of management's alignment with shareholder interests, despite the pre-planned nature of the sales.

Key Dates

Keywords

GALT, Galectin Therapeutics, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Khurram Jamil, 10b5-1 Plan, Restricted Stock Units, Equity Compensation